Literature DB >> 11357893

Inhibition of the transcription factors AP-1 and NF-kappaB in CD4 T cells by peroxisome proliferator-activated receptor gamma ligands.

P Wang1, P O Anderson, S Chen, K M Paulsson, H O Sjögren, S Li.   

Abstract

The peroxisome proliferator-activated receptor gamma (PPARgamma), a member of the nuclear hormone receptor superfamily, is essential for adipocyte differentiation and glucose homeostasis. PPARgamma has been found recently to regulate macrophage activation in response to mitogens and inflammation. Our study shows PPARgamma to be preferentially expressed in the nuclei of resting T cells and to increase upon activation of T cells by either anti-CD3 and anti-CD28 or phorbol myristyl acetate (PMA). We also found the PPARgamma ligand ciglitizone to attenuate the activation of T cells by inhibiting cytokine gene expression and anti-CD3 and anti-CD28 or PMA-induced proliferative responses. Inhibition of both the proliferative response and inflammatory cytokine expression in CD4 T cells was correlated with suppression of the activated transcription factors AP1 and NF-kappaB. PPARgamma ligands also strongly inhibited SEA-induced Vbeta3 T cell activation in vivo. These results, together with previous findings of the inhibitory effect of PPARgamma ligands on activated macrophages, provide clear evidence for PPARgamma as a negative regulator of the inflammatory activation of both macrophage and T cells. PPARgamma may thus be a potential therapeutic target for the treatment of autoimmunity.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11357893     DOI: 10.1016/s1567-5769(01)00015-7

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  30 in total

Review 1.  Significance of anti-inflammatory effects of PPARgamma agonists?

Authors:  G Rogler
Journal:  Gut       Date:  2006-08       Impact factor: 23.059

Review 2.  Angiotensin II AT(1) receptor blockers as treatments for inflammatory brain disorders.

Authors:  Juan M Saavedra
Journal:  Clin Sci (Lond)       Date:  2012-11       Impact factor: 6.124

Review 3.  PPARγ Regulation in Hypertension and Metabolic Syndrome.

Authors:  Madeliene Stump; Masashi Mukohda; Chunyan Hu; Curt D Sigmund
Journal:  Curr Hypertens Rep       Date:  2015-12       Impact factor: 5.369

4.  Telmisartan ameliorates lipopolysaccharide-induced innate immune response through peroxisome proliferator-activated receptor-γ activation in human monocytes.

Authors:  Tao Pang; Julius Benicky; Juan Wang; Martina Orecna; Enrique Sanchez-Lemus; Juan M Saavedra
Journal:  J Hypertens       Date:  2012-01       Impact factor: 4.844

5.  15-deoxy-Delta12,14-prostaglandin J2 (15d-PGJ2) and ciglitazone modulate Staphylococcus aureus-dependent astrocyte activation primarily through a PPAR-gamma-independent pathway.

Authors:  Nirmal K Phulwani; Douglas L Feinstein; Vitaliy Gavrilyuk; Candan Akar; Tammy Kielian
Journal:  J Neurochem       Date:  2006-12       Impact factor: 5.372

6.  IL-10 mediates rosiglitazone-induced kidney protection in cisplatin nephrotoxicity.

Authors:  Myung-Gyu Kim; Ha Na Yang; Hye-Won Kim; Sang-Kyung Jo; Won Yong Cho; Hyoung-Kyu Kim
Journal:  J Korean Med Sci       Date:  2010-03-19       Impact factor: 2.153

7.  PPAR-gamma receptor ligand induces regression of endometrial explants in baboons: a prospective, randomized, placebo- and drug-controlled study.

Authors:  Dan I Lebovic; Jason M Mwenda; Daniel C Chai; Michael D Mueller; Allessandro Santi; Senait Fisseha; Thomas D'Hooghe
Journal:  Fertil Steril       Date:  2007-05-11       Impact factor: 7.329

8.  Evaluation of suppressive and pro-resolving effects of EPA and DHA in human primary monocytes and T-helper cells.

Authors:  Anke Jaudszus; Michael Gruen; Bernhard Watzl; Christina Ness; Alexander Roth; Alfred Lochner; Dagmar Barz; Holger Gabriel; Michael Rothe; Gerhard Jahreis
Journal:  J Lipid Res       Date:  2013-01-24       Impact factor: 5.922

Review 9.  The non-human primate model of endometriosis: research and implications for fecundity.

Authors:  A G Braundmeier; A T Fazleabas
Journal:  Mol Hum Reprod       Date:  2009-07-24       Impact factor: 4.025

10.  The role of 25-hydroxyvitamin D deficiency in promoting insulin resistance and inflammation in patients with chronic kidney disease: a randomised controlled trial.

Authors:  William G Petchey; Ingrid J Hickman; Emma Duncan; Johannes B Prins; Carmel M Hawley; David W Johnson; Katherine Barraclough; Nicole M Isbel
Journal:  BMC Nephrol       Date:  2009-12-10       Impact factor: 2.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.